In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Andexanet Alfa, an Investigational Universal Antidote for Reversal of Anticoagulation of Factor Xa Inhibitors in Healthy Human Volunteers

    Final Number:
    176

    Authors:
    Mark Crowther; Alex Gold; Genmin Lu; Janet Leeds; Brian Wiens; Vandana Mathur; Janice Castillo; Pamela Conley; Stuart Connolly; John Curnutte

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2016 Annual Meeting

    Introduction: Direct FXa inhibitors have demonstrated convincing anticoagulant efficacy. However, risk of major bleeding is a concern and no specific antidotes are available for reversal. Andexanet alfa (AnXa), a recombinant modified FXa, is an investigational specific antidote for FXa inhibitors. We report data from the ANNEXA™ Phase 3 registration studies in older healthy subjects anticoagulated with apixaban (apix) or rivaroxaban (riva).

    Methods: ANNEXA–A&R were two Phase 3, randomized, double-blind, placebo-controlled studies of AnXa in healthy subjects age 50 to 75 administered either apixaban or rivaroxaban. Andexanet dose selection was based on Phase 2 data and PK/PD modeling, which will be presented. In ANNEXA™-A, subjects were treated with apix 5mg BID for 4 days to achieve steady state concentrations. AnXa (Part 1: 400mg bolus; Part 2: 400mg bolus plus 4mg/min x 2hr infusion) or placebo was administered on Day 4, 3 hrs after the last apix dose. In ANNEXA™-R, subjects were treated with riva 20mg QD for 4 days to achieve steady state concentrations. AnXa (Part 1: 800mg bolus; Part 2: 800mg bolus plus 8mg/min x 2hr infusion) or placebo was administered on Day 4, 4 hrs after the last riva dose. Safety data were collected through Day 43.

    Results: ANNEXA-A&R enrolled 63 and 82 subjects, respectively. The primary efficacy endpoint, percent change from baseline in anti-FXa activity to nadir (Part 1: between 2-5 min post-bolus; Part 2: between 10 min prior to and 5 min after the end of the continuous infusion) was met for each part with high statistical significance (p<0.0001 vs. placebo). Additional efficacy endpoints, including reduction in plasma free inhibitor concentration and restoration of thrombin generation, were also met. There were no serious adverse events, thrombotic events, or antibodies to FX or FXa. The andexanet PK/PD model accurately predicted the riva and apix anti-FXa activity observed in this study.

    Conclusions: ANNEXA-A&R achieved all primary and secondary endpoints with high statistical significance. AnXa treatment resulted in rapid and sustained reversal of both apix and riva-induced anticoagulation. A Phase 3b/4 confirmatory study (ANNEXA-4) in patients with acute major bleeds is ongoing.

    Patient Care: Provide a treatment option for patients treated with Factor Xa inhibitors that experience a major bleed, including intracranial hemorrhages

    Learning Objectives: Provide a treatment option for patients treated with Factor Xa inhibitors that experience a major bleed, including intracranial hemorrhages

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy